Characteristics of AML Patients at MD Anderson Cancer Center
| . | VEGF Measured (%) . | VEGF not Measured (%) . | P Value . |
|---|---|---|---|
| Number | 99 | 167 | |
| Median age | |||
| Zurbrod >2 | 14 (14) | 23 (14) | .94 |
| APL | 9 (9) | 12 (7) | .58 |
| t(8;21), or inv(16), or t(15;17) | 17 (17) | 15 (9) | .05 |
| Normal karyotype | 34 (35) | 59 (35) | .99 |
| −5/−7 | 23 (24) | 33 (20) | .50 |
| Other karyotype | 25 (26) | 60 (36) | .07 |
| AHD | 34 (34) | 71 (43) | .25 |
| WBC (×109/L) | 14.10 | 6.0 | <.0001 |
| % Circulating blasts | 31 | 9 | <.0001 |
| Treatment | |||
| Idarubicin + Ara-C | 30 | 34 | |
| Fludarabine + Idarubicin + Ara-C | 53 | 109 | .24 |
| Topotecan + Ara-C | 7 | 12 | |
| APL treatment | 9 | 12 | |
| % CR | 65 (66) | 102 (61) | .453 |
| Deaths days 1-35 | 14 (14) | 35 (21) | .165 |
| Median CR duration (wk) | 46 | 51 | .38 |
| Median survival (wk) | 45 | 33 | .33 |
| Median follow-up time censored patients | 89 wk | 81 wk |
| . | VEGF Measured (%) . | VEGF not Measured (%) . | P Value . |
|---|---|---|---|
| Number | 99 | 167 | |
| Median age | |||
| Zurbrod >2 | 14 (14) | 23 (14) | .94 |
| APL | 9 (9) | 12 (7) | .58 |
| t(8;21), or inv(16), or t(15;17) | 17 (17) | 15 (9) | .05 |
| Normal karyotype | 34 (35) | 59 (35) | .99 |
| −5/−7 | 23 (24) | 33 (20) | .50 |
| Other karyotype | 25 (26) | 60 (36) | .07 |
| AHD | 34 (34) | 71 (43) | .25 |
| WBC (×109/L) | 14.10 | 6.0 | <.0001 |
| % Circulating blasts | 31 | 9 | <.0001 |
| Treatment | |||
| Idarubicin + Ara-C | 30 | 34 | |
| Fludarabine + Idarubicin + Ara-C | 53 | 109 | .24 |
| Topotecan + Ara-C | 7 | 12 | |
| APL treatment | 9 | 12 | |
| % CR | 65 (66) | 102 (61) | .453 |
| Deaths days 1-35 | 14 (14) | 35 (21) | .165 |
| Median CR duration (wk) | 46 | 51 | .38 |
| Median survival (wk) | 45 | 33 | .33 |
| Median follow-up time censored patients | 89 wk | 81 wk |